Evaluating the safety and effectiveness of new drugs

American Family Physician

Volumn 82, Issue 1, 2011, Pages 53-57

  Pegler, Scott ^a   Underhill, Jonathan ^b  

^a MORRISTON HOSPITAL   (United Kingdom)

^b National Prescribing Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; CETIRIZINE; CITALOPRAM; DESLORATADINE; DIETHYLSTILBESTROL; DOXAZOSIN; ESCITALOPRAM; ESOMEPRAZOLE; FEXOFENADINE; FOSFESTROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOCETIRIZINE; LORATADINE; NEW DRUG; OMEPRAZOLE; PLACEBO; ROFECOXIB; TERFENADINE; THALIDOMIDE; THIAZIDE DIURETIC AGENT; TORCETRAPIB; PRESCRIPTION DRUG;

ADENOCARCINOMA; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG MARKETING; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; PHOCOMELIA; PRESCRIPTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; UNSPECIFIED SIDE EFFECT; VAGINA CARCINOMA; ARTICLE; CLINICAL PRACTICE; DRUG APPROVAL; DRUG TOXICITY; TREATMENT OUTCOME;

DRUG APPROVAL; DRUG TOXICITY; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; TREATMENT OUTCOME;

EID: 77954735343     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-19. (Pubitemid 38869995)
2. Vervloet D, Durham S. Adverse reactions to drugs. BMJ. 1998;316(7143):1511-1514.
3. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002,287(17):2215-2220. (Pubitemid 34441937)
4. Bennett CL, Nebeker JR, Lyons EA, et al. The Research on Adverse Drug Events and Reports (RADAR) project. JAMA. 2005;293(17):2131-2140. (Pubitemid 40617066)
5. Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963-2004. CMAJ. 2005;172(6):765-767.
6. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ. 1998;316(7140):1295-1298.
7. Ebell MH, Barry HC, Slawson DC, Shaughnessy AF. Finding POEMs in the medical literature. J Fam Pract. 1999;48(5):350-355.
8. Pegler S, Underhill J. Evaluating promotional material from industry: an evidence-based approach. Pharm J. 2005;274:271-274. (Pubitemid 40378658)
9. Packer M, Carver JR, Rodeheffer RJ, et al.; PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325(21):1468-1475.
10. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [published corrections appear in JAMA. 2003;289(2):178, and JAMA. 2004;291(18):512-514]. JAMA. 2002;288(23):2981-2997.
11. Ghali WA, Rodondi N. HDL cholesterol and cardiovascular risk. BMJ. 2009;338:a3065.
12. Anderson GL, Limacher M, Assaf AR, et al.; Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in post-menopausal women with hysterectomy the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712.
13. Nissen SE, Tardif JC, Nicholls SJ, et al.; ILLUSTRATE Investigators. Effect of torcetrapib on the progression of coronary atherosclerosis [published correction appears in N Engl J Med. 2007;357(8):835]. N Engl J Med. 2007;356(13):1304-1316.
14. Maynard A. Evidence-based medicine: an incomplete method for informing treatment choices. Lancet. 1997;349(9045):126-128. (Pubitemid 27023440)
15. National Collaborating Centre for Primary Care. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence. London, England: National Institute for Health and Clinical Excellence; January 2009.
16. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals: structured review of accessibility of underlying absolute risks. BMJ. 2006;333(7581):1248.
17. New drugs from old. Drug Ther Bull. 2006;44(10):73-77.
18. Garattini S, Bertele' V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet. 2007;370(9602):1875-1877. (Pubitemid 350180009)